Objective: The aims of the present study were: (1) to determine whether short-term supplementation of b-carotene (BC) or vitamin E (VE; a-tocopherol) would result in their respective accumulation in normal colonic mucosa and in adenomatous polyps; (2) to determine whether the intake of BC would interfere with the concentration of VE in these target tissues. Design: Blood and colonic biopsy samples were taken before and after supplementation. Subjects: Eighteen volunteers with colonic adenomatous polyps were enrolled into this study. Interventions: The supplementation lasted for 43 days and patients were examined over the whole period. Subjects were randomised into four groups according to the four different supplementations: placebo, natural BC (25 000 IU=day), natural VE (400 IU=day), combination BC=VE. Results: Initially we were aiming for recruitment of 20 patients in each group, however after 2 y of study (1997 -1999), we terminated the study because of slow recruitment and analysed the data. In placebo subjects after supplementation, the plasma concentrations of BC and VE remained unchanged, however only two patients were recruited in this group and therefore we did not include this group in our final analysis. In BC group, the plasma BC concentrations increased significantly (P < 0.001), while VE concentrations were unchanged. In VE group, VE concentrations increased (P < 0.01) and BC did not change, and in BC=VE group both BC (P < 0.001) and VE levels (P < 0.01) increased significantly. After supplementation, the tissue concentration of BC in normal colonic mucosa in BC group increased significantly (P < 0.01) while the VE concentration did not change. In VE group, the concentration of VE in normal colonic mucosa increased slightly but did not reach statistical significance. However, VE concentration increased significantly (P < 0.05) in the polyps of this group. In BC=VE group, in which patients received the combination treatment, the BC concentration of normal colonic mucosa increased (P < 0.05) but, surprisingly, the VE concentration decreased significantly (P < 0.01). Interestingly in the polyps, although the BC concentration increased (P < 0.01), the concentration of VE was reduced moderately but did not reach statistical significance. Conclusions: Supplementation of BC in doses used in this study may have significantly interfered with the VE concentration in the examined tissue and probably with its metabolic pathway.
Introduction
Early epidemiological studies (Peto et al, 1981; Gey et al, 1987; O'Sullivan et al, 1991; Meydani et al, 1994; Van Poppel, 1996; Krinsky, 1998) brought up an important dietary issue, which was whether carotenoids and particularly b-carotene (BC) could reduce cancer rate (Jandacek, 2000) . These early observations were followed by a large body of nutritional data showing that intake of foods rich in BC was associated with reduced rate of certain cancers (Slattery et al, 2000) .
Colon cancer and colonic adenomatous polyps are among the most common neoplasia in Western populations and colon cancer-related death ranks second to lung cancer.
Despite a significant link to genetic factors, in the majority of cases diet is considered the major risk factor in increased incidence of this type of cancer. It is of interest that, when populations living in areas with low risk for colon rectal cancer move to areas where this type of cancer is of high incidence and adopt the local diet habits, they start to develop the same high risk of cancer (World Cancer Research Fund in association with American Institute for Cancer Research, 1997) .
Accordingly, within a few years, several clinical interventional studies were started to see whether oral administration of BC supplementation in doses ranging from 15 to 30 mg alone or in combination with other antioxidants is able to reduce the cancer rate in human subjects (Mobarhan et al, 1994; Albanes et al, 2000) . The results of these studies were rather disappointing in most cases (Pryor et al, 2000) , and unfortunately there was also evidence of enhancement of lung carcinogenicity in studied subjects who were actively smoking. In the colon polyp studies no effect on colon cell proliferation or the rate of polyp formation was noted and in one study there was evidence that BC supplementation may affect the tissue concentration of a-tocopherol (Xu et al, 1992) .
Further studies have suggested that intake of supplemental doses of BC may induce production of cleavage and oxidative compounds that could interfere with retinoid signalling, thus enhancing the effects of carcinogens. The question whether some of the effects of BC could also be secondary to its interactions with other important carotenoids such as lutein, a-carotene, lycopene or vitamin E (VE) at the target tissues, has not yet been fully answered. Colonic adenomatous polyps are considered precancerous lesions and are accessible to biopsy and resection without significant risk to the patients, and are indeed good models for the study of the effects of chemopreventive agents. In fact they have been studied previously for evaluation of the effects of BC and other vitamins, and non-steroidal anti-inflammatory agents Almendingen et al, 2001; Nierenberg et al, 1994; Cahill et al, 1993; Pappalardo et al, 1997) .
Our hypothesis in this study is that intake of BC may interfere with tissue uptake or storage of VE or other carotenoids, thus reducing the ability of target tissue to deal with carcinogens and oxidative events.
The aim of the present study was two-fold: to determine whether short-term supplementation of BC or VE would result in their respective accumulation in normal colonic mucosa and in adenomatous polyps; and to determine whether the intake of BC would interfere with the concentration of VE in these target tissues.
Materials and methods
Subjects and study design Initially the study was designed to recruit 20 patients for each group. However, after 2 y of intensive work we could identify only 23 subjects for the study. At the end of 2 y the study was terminated because of the slow rate of recruitment in the last 6 months of the study and realisation that further delay was not justified and would not have increased the number of cases. We proceeded with statistical analyses of the data. In the framework of our clinical practice of gastroenterology, seeing patients requiring colonoscopy for clinical indications, we asked our non-smoking patients, who had been found to have benign adenomatous polyps, to participate in a randomised short-term study, to see whether intake of BC, alone or in combination with VE, affected the concentration of vitamin A and VE in plasma, normal colon mucosa and adenomatous polyps and to evaluate whether the interactions between BC and a-tocopherol interfere with absorption and uptake in normal colon mucosa and adenomatous polyps.
Of 23 subjects with a diagnosis of colonic polyps identified at the 2nd Surgical Institute, Faculty of Medicine, University 'La Sapienza' of Rome, three subjects who had other pathological disease (biliary calculosis, malabsorption syndromes, hepatic diseases) were excluded from the study. In addition two other subjects on vitamin supplements were also excluded. The remaining 18 (10 males, eight females, age range 28 -70) volunteers all agreed to be enrolled into this study, giving their informed consent. They were examined over a period of 43 days under direct supervision of one of the authors (Professor Pappalardo). This study was approved by the National Research Institute for Food and Nutrition Internal (ethical committee) review board. The subjects were allowed to follow their usual diet without any restrictions except herbs or vitamin supplementation. Extra virgin olive oil intake was limited to 2 spoonfulls a day and wine was permitted, not exceeding 20 -30 g daily. All the subjects were non-smokers.
The subjects followed a diet with low fibre residue for 3 days before endoscopy and ingested laxative tablets 12 h prior to endoscopy. In all subjects, fasting venous blood (5 ml) was obtained before colonoscopy for the determination of some plasma carotenoids, a-tocopherol and retinol. At the time of endoscopy, multiple biopsies (5 -15 mg) were obtained both from the intact mucosa of the sigmoid colon (25 cm from anal venge) and from colonic polyps. The polyp(s) was not resected during the initial colonoscopy and the biopsy was sent for histological examination as well as for the determination of BC and a-tocopherol. Subjects were asked to consume by mouth daily before breakfast one capsule containing BC, one capsule containing natural VE or both. The oral supplementation lasted for 43 days for all groups: two subjects received placebo supplementation; the BC group included five subjects receiving natural BC 25 000 IU per capsule per day; the VE group included five subjects receiving natural VE (D-a-tocopherol acetate) supplementation 400 IU per capsule per day; finally, the BC=VE group included six subjects receiving combined supplementation 25 000 IU mg per day plus 400 IU per day, respectively, for natural BC and natural VE (Cotnis Nutrition and Health Group). On day 43, the colonoscopy was repeated and the b-carotene and a-tocopherol F Simone et al polyp(s) was resected and fasting blood samples were also collected. All of the tissues were washed with normal saline solution to remove contaminating blood before analysis. The tissues were cut into pieces, weighed and stored at 7 70 C until analysis. Plasma samples were stored at 7 70 C until analysis. The polyps were also examined hystologically.
Methodologies of analysis
The tissues were homogenised and saponified by the addition of 10 N KOH and 2% pyrogallol in methanol and heating at 65 C for 60 min. Two mixture extractions were made using 2 ml hexane twice. Then the extracts were combined and washed with water to remove KOH. Plasma was extracted with 2 ml of hexane containing butylated hydroxytoluene twice (0.01% w=v). The samples (tissue and plasma) were dried and reconstituted in the mobile phase. Because of the obligatory saponification, this method does not allow for the measurement of tissue retinol concentration.
The determinations of the plasma (lutein plus zeaxanthin, cryptoxanthin, lycopene, a-carotene, BC, retinol and a-tocopherol) and tissue (BC and a-tocopherol) concentrations were carried out by high performance liquid chromatography techniques (HPLC) fully described elsewhere (Maiani et al, 1995; Stacewicz-Sapuntzakis et al, 1987) . The laboratory of the Human Nutrition Unit participates in the international standards program of the National Institute of Standards and Technology (NIST, Gaithersburg, MD, USA). Therefore, the precision and reproducibility of BC, retinol and VE determinations were evaluated with NIST USA reference material (SRM 968 C level 2) and came within the limits set for them -1.6, 8.0 and 1.1%, respectively (expressed as variation coefficients). All measurements were performed in duplicate assay.
The results for tissue concentration for BC and atocopherol are expressed as ng=g wet tissue and mg=g wet tissue, respectively. The plasma concentration of carotenoids is expressed as mg=dl of plasma and a-tocopherol plasma concentration as mg=dl.
Statistical analysis
Because of small number of cases in placebo treatment, these subjects were excluded from further analysis and we compared the data in the remaining three groups. The data are reported as mean AE s.d. The analysis of the data was conducted by the use of parametric test (ANOVA variance analysis and paired t-test) and non-parametric test (Wilcoxon test). The ANOVA and Wilcoxon test were used to determine differences among groups both before and after supplementation. Differences among values before and after supplementation for subjects within the same group were determined using paired t-test.
Results
As was mentioned earlier the placebo subjects did not enter in to the statistical analysis. All the data are characterised by a great inter-individual variability that is common to other similar studies. Physical characteristics of patients entering the study are shown in Table 1 .
The comparison among groups showed that the subjects in the BC group were less tall (P < 0.05) than subjects in the VE group. All patients were asked to bring back their medication bottle containing either placebo or capsules of VE or BC. The compliance was checked in each clinical visit by a count of remaining capsules in the bottles. The compliance was similar in all groups, 89 -97%. Tables 2 and 3 also compare BC and VE concentrations in tissue for all groups before and after provitamin, vitamin or multiple supplementation (BC=VE). The values are quite similar before supplementation; after BC supplementation the concentrations of BC are significantly higher in those subjects belonging to the BC group and BC=VE group than to those in the VE group.
In placebo subjects (data not shown), after supplementation the concentration of BC and a-tocopherol in healthy tissue and colonic polyps tissue were not significantly different from those observed before supplementation. Normal colonic mucosa (Table 2 ) behaved in a different way according to the different supplementation. Subjects who were given BC supplementation (BC group) showed a significative increase of the concentrations of BC (P < 0.01) in normal b-carotene and a-tocopherol F Simone et al colonic tissue, while tissue concentrations of the a-tocopherol were similar before and after BC supplementation.
In the VE group, who received only VE supplementation, the mucosal concentrations of the BC were similar before and after VE supplementation and surprisingly supplementation did not produce significant increase of tissue a-tocopherol concentrations. After combined supplementation (BC=VE group), BC concentrations were significantly higher (P < 0.05) compared to baseline. However, the tissue a-tocopherol concentrations were decreased significantly (P < 0.01) as compared to values prior to supplementation. Table 3 shows the tissue concentration (mean AE s.d.) in colonic adenomatous polyps of BC and a-tocopherol before and after supplementation. BC supplementation produced a similar result to that in normal colonic mucosa. As a result of BC supplementation, the tissue BC concentration was significantly increased (BC group, P < 0.001; BC=VE group, P < 0.01) as compared to baseline values. However, the concentration of a-tocopherol remained similar in the BC group before and after supplementation and relatively lower in BC=VE group with respect to baseline values. Administration of VE, in the VE group, resulted in a significative increase in colonic polyp VE concentration (P < 0.05) after 43 days of supplementation. In this group there was also no significant change in BC concentrations. Finally, the combined supplementation in BC=VE group produced a significant increase (P < 0.01) in BC concentrations, while no substantial effect was recorded on tissue levels of a-tocopherol.
In Table 4 plasma values are shown. Before supplementation, plasma values of BC were similar in all groups. After supplementation, BC levels increased in the BC and BC=VE groups (P < 0.001), but not in the VE group. For a-tocopherol there were no differences among the different groups.
In plasma (Table 4 ; results expressed as mean AE s.d.), supplementation with BC alone produced a significant improvement in the circulating levels of BC (P < 0.001), but no effect was observed as on plasma a-tocopherol levels. Similarly, a-tocopherol supplementation alone in the VE group produced a significant (P < 0.01) increase in the circulating levels of a-tocopherol itself and a mild but significant decrease in BC levels. The combined supplementation produced a striking increase in BC levels and also a significant improvement of plasma a-tocopherol. No change occurred in plasma concentration of retinol in all the studied groups (data not shown).
Discussion and conclusion
The effect of BC on a-tocopherol absorption, plasma and tissue concentration is rather controversial (Parker, 1996) . The general point of view is that BC does not interfere with the metabolism of VE. However, Xu et al, (1992) reported a decrease in plasma VE levels in patients supplemented with BC for a period of 9 months with doses ranging from 15 to 60 mg=daily. In other long-term BC clinical trials no significant effect of BC on plasma VE was noted (Willett et al, 1983; Greenberg et al, 1990) . Nevertheless, Mobahran et al, (1994) reported a decline in concentration of BC in colonic mucosa of patients supplemented with BC (30 mg) for a period of 3 months.
VE and BC have a synergic antioxidant effect (Hercberg et al, 1998; Pallozza & Krinski 1992) against the lipidic proxidation. On a hypothetical basis, a mixture of both antioxidants can inhibit synergistically the lipid peroxidation produced by peroxyl radicals.
BC and a-tocopherol could exert their synergistic effect by acting on different parts of the cellular membrane (a-tocopherol on the surface and BC inside). Furthermore, a-tocopherol is able to scavenge peroxyl radicals derived from BC metabolism. Our study is in agreement with this hypothesis; in fact, in polyps, after combined supplementation, only BC levels were increased, while a-tocopherol concentration remained quite similar to baseline levels. This behaviour could signify an enhanced use of a-tocopherol in scavenging excess BC radicals. It is of interest that this happened particularly in the polyps, where the production of free radicals may be increased. As for as the interaction between BC and a-tocopherol, it is possible to speculate that the two b-carotene and a-tocopherol F Simone et al molecules interact in protecting the cell membranes and low-density lipoprotein from free radical attack. It remains to be studied whether precancerous or cancerous cells have special requirements of these two molecules and if they act in a particular way in these cells.
In conclusion, the results of this study indicate that supplementation of BC in doses used in this study significantly interferes with the storage and probably physiological pathway of VE in the examined tissues. Whether BC or its pro-oxidant cleavage products increased the destruction of VE in these tissues, or BC by itself interfered with tissue uptake of VE, remains to be studied further.
